

Information For the Use of  
Menotrophin (150IU) Injection

# Fertiedge HMG 150 injection

**Brand Name:** Fertiedge HMG 150 Injection

**Dosage Form:** Injection

**Composition:**

**Each vial contains:**

- Menotrophin IP 150 IU

(Human Menopausal Gonadotrophin containing Follicle Stimulating Hormone and Luteinizing Hormone activity)

---

**Description:**

Fertiedge HMG 150 Injection contains Menotrophin, a gonadotrophin preparation with both follicle stimulating hormone (FSH) and luteinizing hormone (LH) activity. It is indicated for the treatment of infertility in women and men due to gonadotrophin deficiency or ovulatory disorders. It helps in stimulating follicular development, ovulation, and spermatogenesis.

---

**Indications:**

Indicated for the treatment of:

- Female infertility associated with anovulation
- Controlled ovarian stimulation in assisted reproductive techniques (ART)
- Male hypogonadotropic hypogonadism for stimulation of spermatogenesis

It helps in promoting reproductive hormone activity and improving fertility outcomes.

---

**Dosage & Administration:**

Dosage should be individualized and administered strictly under the supervision of a fertility specialist.

Administer by subcutaneous or intramuscular injection as directed by the physician.

Regular monitoring through ultrasound and hormonal assessment is recommended during therapy.

---

**Pharmacological Action:**

- Menotrophin contains FSH and LH activity that stimulates ovarian follicular growth and maturation in females.
- In males, it supports spermatogenesis by stimulating testicular function.
- LH activity contributes to ovulation and steroid hormone production.

These combined effects help in enhancing fertility and reproductive function.

---

**Side Effects:**

Common side effects include injection site reactions, abdominal discomfort, headache, and nausea.

In females, ovarian hyperstimulation syndrome (OHSS) may occur.

Multiple pregnancies and thromboembolic events have been reported rarely.

---

**Precautions & Warnings:**

- Use only under specialist supervision
  - Monitor ovarian response regularly to reduce risk of OHSS
  - Use with caution in patients with endocrine disorders or thromboembolic risk
  - Not indicated in primary ovarian failure or uncontrolled thyroid/adrenal dysfunction
  - Discontinue treatment if severe ovarian enlargement occurs
- 

**Drug Interactions:**

Concomitant use with other fertility agents such as clomiphene citrate may enhance ovarian response.

Inform the physician about all concurrent medications.

---

**Storage:**

Store at 2°C–8°C under refrigeration.

**Do not freeze.**  
**Protect from light.**  
**Keep out of reach of children.**

Manufactured in India for:



**Cafoli Lifecare Pvt. Ltd.**

**(An ISO 9001: 2015 Certified Co.)**

Plot no.: 367-FF, Industrial Area Phase-I, Panchkula-134113

TM: Trademark Applied for